Lung Cancer
In March 2021, the FDA approved Lorbrena (lorlatinib), a third-generation ALK inhibitor, for first-line treatment of patients with non–small-cell lung cancer and ALK mutation. Lorbrena was previously approved for the second- or third-line treatment for this patient population. Read More ›
In February 2021, the FDA approved Cosela (trilaciclib) as the first CDK4/6 inhibitor to reduce the risk of chemotherapy-induced myelosuppression in adults with extensive-stage small-cell lung cancer. Cosela can prevent damage to bone marrow cells by blocking the CDK4/6 enzyme. Read More ›
By Treven Pyles
Learning about lung cancer risks is important. An issue that needs more awareness is occupational exposure to harmful chemicals and the negative effects such exposure has on our health. Read More ›
The immunotherapy Libtayo received FDA approval as first-line treatment for patients with advanced or metastatic non–small-cell lung cancer and high PD-L1 expression. Read More ›
When Veronica Brent had a constant cough and shortness of breath from walking, her daughter suggested she should have a chest x-ray. The x-ray showed she had lung cancer, and a biopsy showed she had cancer on the pancreas. She was concerned how to break the news to the family. Read More ›
In February 2021, the FDA approved Tepmetko (tepotinib), a new oral targeted therapy, for the treatment of all adults with metastatic non–small-cell lung cancer and MET exon 14 alterations. Tepmetko is the second MET inhibitor that has been approved by the FDA. Read More ›
In December 2020, the FDA approved Tagrisso (osimertinib) for adjuvant therapy (continued therapy to prevent cancer recurrence) after surgical removal of the tumor, in patients with non–small-cell lung cancer and EGFR exon 19 deletions or exon 21 L858R mutations. Tagrisso was previously approved for the treatment of other types of lung cancer. Read More ›
A treatment combination containing the immunotherapy drugs Opdivo (nivolumab) and Yervoy (ipilimumab) received 2 approvals in non–small-cell lung cancer (NSCLC) in the past year. Read More ›
By Chase Doyle
A chest x-ray and a CT scan revealed a diagnosis of stage IV (advanced) non–small-cell lung cancer after John Doll was experiencing shortness of breath and a lingering cold. Read More ›
In her introduction to the November 2020 issue that is focused on lung cancer, Lillie D. Shockney discusses the articles and dispels the common assumption that only smokers get lung cancer. Read More ›